BioPharma Credit Stock
BioPharma Credit PLC
Company data
- Sector
- Financial Services
- Industry
- Asset Management
- Country
- United Kingdom
- CEO
- Pedro Gonzalez de Cosio
- Employees
- 0
- Market cap
- $1.1 B
- IPO
- 27/03/2017
As an investment trust, BioPharma Credit PLC primarily allocates its portfolio to debt assets that generate interest. The security for these investments is provided by royalty payments or other cash flows stemming from the sales of officially approved life sciences products. The firm was established in 2016 and…
BioPharma Credit stock: price history
1D
+0.0%
1W
+1.4%
1M
+1.0%
6M
+4.3%
YTD
+7.0%
1Y
+5.8%
2Y
+12.9%
5Y
+0.4%
10Y
–
Next earnings date
Next earnings date
No date known
Volatility around earnings
~32% stronger price swings than usual
Ask the agents about BioPharma Credit
BioPharma Credit stock metrics
P/E
10.28
P/B
0.97
EV/EBITDA
18.06
RETURN ON EQUITY
4.4%
NET MARGIN
87.7%
DEBT/EQUITY
0
DIVIDEND YIELD
8.6%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
86.4%
FLOAT SHARES
969,071,750
AVG. DAILY VOLUME (30D)
1,569,838
Dividends
Comparable stocks
Frequently asked questions about BioPharma Credit stock
What does BioPharma Credit do?
BioPharma Credit PLC is a company in the Financial Services sector, Asset Management industry, headquartered in United Kingdom.
The IPO was on 27/03/2017; the stock trades on LSE under the ticker BPCR.L.
When does BioPharma Credit report next?
Around past earnings, price swings were roughly 32% stronger than usual.
Does BioPharma Credit pay a dividend?
Yes. The last dividend was US$0.02 per share, ex-date 08/10/2026, paid on 06/11/2026.
The dividend yield is 8.6% (as of 30/06/2026).
Which stocks are comparable to BioPharma Credit?
Comparable stocks include Schroders, Man Group, International Public Partnerships, Greencoat UK Wind, IntegraFin Holdings, Molten Ventures, GCP Infrastructure Investments and Foresight Environmental Infra Ord.
How can I get BioPharma Credit stock analyzed?
Clicking "Analyze stock" lets five strategies assess BioPharma Credit against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.